clinical dementia rating - sum of boxes (CDR-SB)
Jump to navigation
Jump to search
Interpretation
- range 0-18, higher scores indicate greater impairment
- score of 3.2 is consistent with early Alzheimer's disease
More general terms
References
- ↑ George J Alzheimer's Drug Slows Decline, Trial Data Show. Lecanemab met primary and secondary endpoints, but was associated with adverse events. MedPage Today November 30, 2022 https://www.medpagetoday.com/neurology/alzheimersdisease/101972
van Dyck CH, Swanson CJ, Aisen P Lecanemab in Early Alzheimer's Disease. N Engl J Med 2022. Nov 29. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36449413 https://www.nejm.org/doi/full/10.1056/NEJMoa2212948